| INTRODUCTION
Serum antibody titres are often used as correlates of protection for influenza. 1 Three commonly used serological assays for detecting influenza-specific serum antibodies are single radial haemolysis (SRH), haemagglutinin inhibition (HAI) and microneutralization (MN), of which SRH and HAI are the most widely used. The SRH assay utilizes antibody diffusion in agar gel to measure the antibody content of test sera. 2, 3 This method quantifies antibodies by measuring the areas of haemolysis, which, mediated by complement and induced by the antibody-antigen complex, are proportionated to the concentration of antibodies. The HAI assay detects antibodies that can prevent agglutination of erythrocytes. 4 The antibody concentration is quantified as the reciprocal of the highest serum dilution (titre) that inhibits agglutination using a standard assay. MN technique is a form of viral neutralization (VN) that commonly uses cultured Madin-Darby canine kidney (MDCK) cells. 5 The method detects antibodies capable of neutralizing the ability of the virus to enter or replicate in mammalian cells. The quantity of the antibodies is expressed as the reciprocal of the highest serum dilution that induces at least 50% of cytopathic effect in mammalian cell cultures.
By convention, a SRH titre ≥25 mm 2 and an HAI titre of ≥1:40 are considered to be associated with a 50% or higher protection against influenza, while in contrast there are no established thresholds for the MN assay. 6 The cut-off values for SRH and HAI titres were previously adopted by the Committee for Proprietary Medicinal Products for
Human Use (CHMP) as criteria that should be considered for influenza vaccine licensure in Europe. 7 These thresholds however were derived from limited challenge studies in healthy adults performed decades ago and the transferability of these thresholds to other subpopulations, such as children, has never been established. In recent years, there has been growing recognition of the limitation of these established criteria which has led to the abolition of these criteria in the newly developed guideline for influenza vaccine licensing effective February 2017 by CHMP. 8, 9 Until now, there has still been a relative lack of data on all three aforementioned serologic assays as correlates of protection against influenza in young age groups.
Few studies have compared all three assays together on a common serum base. In fact, we found only two such studies and they were limited to equine influenza viruses. In the first study, SRH, HAI and MN tests were performed on sera from horses immunized against two equine influenza viruses including Prague (H7N7) and Miami (H3N8) strains. 10 They found that MN titres of individual sera were and Prague (H7N7) strains. 11 Although there have been studies that compare two of the three assays separately based on human influenza viruses, [12] [13] [14] to the best of our knowledge there has not been a study comparing all three assays together on a common serum base.
We previously reported that for influenza A H3N2, MN is superior to HAI in terms of showing correlates of protection in children and adolescents. 15 In this paper, we sought primarily to understand how SRH titres correlate to protection against influenza A H3N2 infection in children and adolescents. We also compared SRH to HAI and MN.
| MATERIALS AND METHODS

| Participants and serum samples
In this study, we enrolled healthy Hutterite children and adoles- solution of 1.5% agarose was prepared and kept in a water bath at 47.5°C. The resuspended erythrocyte-antigen mixture followed by guinea pig complement (Sigma) was added to the agarose gel. The mixture was then spread onto plates (7.2 cm × 2.3 cm) and incubated for 30 minutes at room temperature and then for 30 minutes at 4°C.
Twenty holes were then made with a 2.25-mm calibrated punch into each plate. Serum samples and controls (6 μL each) were seeded into the holes and returned to 4°C immediately. The plates were then incubated for 18 hours at 4°C in a humid chamber. The plates were then incubated for 90 minutes in the humid chamber at 37°C and the diameter of each haemolysis halo was read in millimetres using the TG Calibrating Viewer.
The HAI assay was performed as previously described using turkey erythrocytes and reference antigens for A/Brisbane/10/2007 (H3N2)-like viruses. 17 MN titres were determined as previously described. 15 For all three assays, we used internally sourced and validated positive and negative controls. We also included back titration of virus for HAI and MN assays.
| Statistical analysis
We evaluated the correlation of protection against influenza of SRH titre by calculating protective effectiveness at each titre threshold using Cox's proportional hazards model, 16 adjusting for clustering using a robust sandwich estimator. The protective effectiveness was defined as (1-hazard ratio) × 100%. We did the same calculation for HAI titre and MN titre thresholds. Traditionally, a HAI titre of 1:40 is accepted in literature as 50% protective against influenza infection. 7 We used 50% protective efficacy as our reference point. We calculated Spearman rank correlation coefficients for antibody levels comparing SRH and HAI antibody levels to MN antibody, levels after vaccination, correcting for ties in ranking. 18, 19 We also used linear regression to estimate the associations between SRH titre value and logtransformed HAI and MN titre values. All analyses were performed in R version 3.0.1 (R Foundation, Vienna, Austria).
| RESULTS
We detected seven (2.0%) PCR-confirmed seasonal H3N2 cases in participants who had received TIV influenza vaccine and 19 (4.9%) in participants who had received hepatitis A vaccine. 
| DISCUSSION
The major finding of this study is that the threshold values for SRH titres as well as HAI titres corresponding to 50% protection against influenza in children ≥3 years and adolescents ≤15 years are much higher than the criteria recommended by CHMP (SRH, >55 mm 2 vs >25 mm 2 ; HAI, >1:640 vs >1:40). 3 This result supports the need for the development of age-specific criteria for these assays.
One recent study also challenged the applicability of these criteria in Children. 20 The authors reported that for children ≤6 years of age, a cut-off of 1:110 HAI titre value many be used to predict the conventional 50% clinical protection rate for seasonal H3N2. Our result of 1:640 may be an overestimate as the sample size in our study was limited and the result is not statistically significant. Currently, there are no established correlates of protection for young age groups in all the three assays. Nevertheless, the new CHMP guideline has abolished the traditional criteria with the recognition that relying on these criteria of measuring protective effectiveness might not be appropriate for various situations and this opens the opportunities to advance the field on correlates of protection in various subpopulations against different influenza strains. 9 Another key finding was that SRH appears to have the worst correlation with protection against influenza H3N2, as the estimates of protective efficacy fluctuated when the cut-off SRH values increased.
The estimates of protective efficacy for MN were relatively stable and consistently higher than those of both SRH and HAI. Our results show that among the three assays, MN titres offer the best correlate of protection against influenza H3N2. The likely explanation, as suggested by Trombetta et al., 6 is that the MN assay detects functional antibodies able to neutralize virus (vs HA binding in the HAI assay and complement fixation in the SRH assay), and therefore measures a greater proportion of the antibodies implicated in protection.
We found the SRH assay to be less sensitive than the MN assay but more sensitive than HAI, as 16% of participants had SRH titres below F I G 1 SRH titre value has the worst correlation with protection against influenza, as the estimates of protective efficacy fluctuated when the cut-offs of SRH titre value increased. The estimates of protective efficacy for MN were relatively stable and consistently higher than those of both SRH and HAI. Protective effectiveness against PCR-confirmed influenza was compared at different SRH, HAI and MN titre cut-offs for seasonal H3N2 (A/Brisbane/10/2007). The hazard ratio (HR) represents the risk at cut-offs greater than or equal to a given titre, relative to levels less than the cut-off, and was calculated using Cox's proportional hazards model, adjusting for participant colony using a robust sandwich estimator. Dotted lines represent the 95% confidence interval and P-values were calculated using standard error estimates from the regression model. The strength of our study is that it provides much needed information regarding SRH as a correlate of protection against influenza. The comparison among the three methods also contributes to the literature considering the limited data available. One limitation of this study is that we had a relatively small sample size considering that sufficient post-vaccination serum for all three assays (ie HAI, SRH and MN) was available for only 15 of the RT-PCR-confirmed cases. Another limitation is that our surveillance did not detect natural exposures (symptomatic or asymptomatic). 
